Effect of the Dual Peroxisome Proliferator-Activated Receptor-α/γ Agonist Aleglitazar on Risk of Cardiovascular Disease in Patients With Type 2 Diabetes - SYNCHRONY


Several dual peroxisome proliferator-activated receptor (PPAR)-α/γ agonists have been clinically developed; however, toxic effects have impeded development beyond phase III clinical trials. The SYNCHRONY study was a phase II clinical trial that sought to assess the therapeutic dose of aleglitazar that would be associated with the best safety and efficacy profile.